Mechelen, Belgium; 22 September 2015: Galapagos NV (Euronext & NASDAQ: GLPG)
presents pre-clinical and Phase 1 results for autotaxin inhibitor GLPG1690 at
the European Respiratory Society Annual Meeting in Amsterdam, Netherlands.
Galapagos expects to file an exploratory Pha ...
↧